P072 (0038) FRONTLINE BRENTUXIMAB VEDOTIN PLUS CHEMOTHERAPY EXHIBITS SUPERIOR MODIFIED PROGRESSION-FREE SURVIVAL VS CHEMOTHERAPY ALONE IN PATIENTS WITH STAGE III OR IV HODGKIN LYMPHOMA: PHASE 3 ECHELON-1 STUDY
Format: | Article |
---|---|
Language: | English |
Published: |
Wiley
2018-10-01
|
Series: | HemaSphere |
Online Access: | http://journals.lww.com/10.1097/01.HS9.0000547919.69672.2a |
Similar Items
-
S200: IMPROVED OVERALL SURVIVAL WITH FIRST-LINE BRENTUXIMAB VEDOTIN PLUS CHEMOTHERAPY IN PATIENTS WITH STAGE III/IV CLASSICAL HODGKIN LYMPHOMA: 6-YEAR ANALYSIS OF ECHELON-1
by: M. Hutchings, et al.
Published: (2022-06-01) -
P009: Improved Overall Survival with First-Line Brentuximab Vedotin plus Chemotherapy in Patients with Advanced Stage III/IV Classical Hodgkin Lymphoma: An Updated Analysis of ECHELON-1
by: Martin Hutchings, et al.
Published: (2022-10-01) -
Brentuximab vedotin in pediatric Hodgkin lymphoma
by: Shuvadeep Ganguly, et al.
Published: (2022-01-01) -
P091 (0159) SERUM sCD30 AND TARC DO NOT CORRELATE WITH PET-BASED RESPONSE ASSESSMENT IN PATIENTS (PTS) WITH STAGE III OR IV CLASSICAL HODGKIN LYMPHOMA (cHL): PHASE 3 ECHELON-1 STUDY OF BRENTUXIMAB VEDOTIN PLUS CHEMOTHERAPY VS CHEMOTHERAPY ALONE
Published: (2018-10-01) -
P088 (0136) BRENTUXIMAB VEDOTIN PLUS CHEMOTHERAPY IN PATIENTS WITH HIGH-RISK ADVANCED-STAGE CLASSICAL HODGKIN LYMPHOMA (CHL): RESULTS OF PRESPECIFIED SUB-GROUP ANALYSES FROM THE ECHELON-1 STUDY
Published: (2018-10-01)